New drugs for the treatment of hypercholesterolaemia

Bibliography

• CHEN Z, PETO R, COLLINS R et al: Serum cholesterol concentration and coronary heart disease in a population with low cholesterol levels. Br. Med. .1. (1991) 303:276–282.
   PubMed Web of Science ®Google Scholar
• VERSCHUUREN WM, JACOBS DR, BLOEMBERG B et al: Serum total cholesterol and long-term coronary heart disease mortality in different culture: twenty five year follow up of the seven countries study. "AMA (1995) 274:131–136.
   PubMed Web of Science ®Google Scholar
• ASSMANN G, CULLEN P, SCHULTE H: The Munster Heart Study (PROCAM): results of follow up at 8 years. Eur. Heart J. (1998) 19(Suppl. A):A2–A11.
   Google Scholar
• DAYTON S, PEARCE ML, HASHIMOTO S et al: A controlled clinical trial of a diet high in unsatured fat in preventing complications of atherosclerosis. Circulation (1969) 39(Suppl. II):1–63.
   Google Scholar
• OLIVER ME HEADY JA, MORRIS JN,COOPER J: A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigations. Br. Heart J. (1978) 40:1069–1118.
   PubMedGoogle Scholar
• LIPID RESEARCH CLINICS PROGRAMS: The lipid research clinics coronary primary prevention trial results: I. Reduction in incidence of coronary heart disease. "AMA (1984) 251:351–364.
   Google Scholar
• FRICK MH, ELO 0, HAAPA K et al: Helsinki heart study: primary-prevention trial with gemfibrozil in middle-age men with dyslipidemia. N Engl. J. Med. (1987) 317:1237–1245.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J, COBBE SM, FORD I et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl. J. Med. (1995) 333:1301–1307.
   PubMed Web of Science ®Google Scholar
• DOWNS JR, CLEARFIELD M, WEIS S et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. "AMA (1998) 279:1615–1622.
   Google Scholar
• HEART PROTECTION STUDY COLLABORATIVE GROUP: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high risk individuals: a randomised placebo controlled trial. Lancet (2002) 360:7–22.
   PubMed Web of Science ®Google Scholar
• RESEARCH COMMITTEE TO THE MEDICAL RESEARCH COUNCIL: Controlled trial of soya-bean oil in myocardial infarction. Lancet (1968) 2(7570):693–700.
   PubMed Web of Science ®Google Scholar
• BURR ML, FEHILY AM, GILBERT JF et al.: Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet (1989) 2(8666):757–761.
   PubMed Web of Science ®Google Scholar
• SCANDINAVIAN SIMVASTATIN SURVIVAL GROUP: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet (1994) 334:1383–1389.
   Google Scholar
• ••A secondary prevention trial showing thatsirnvastatin reduces CHD-related morbidity and mortality in patients with established CHD.
   Google Scholar
• SACKS FM, PFEFFER MA, MOYE LA et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl. J. Med. (1996) 335:1001–1009.
   PubMed Web of Science ®Google Scholar
• ••A secondary prevention trial showing thatpravastatin reduces CHD-related morbidity and mortality in patients with established CHD.
   Google Scholar
• THE LONG-TERM INTERVENTION WITH PRAVASTATIN IN ISCHAEMIC DISEASE (LIPID) STUDY GROUP: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and broad range of cholesterol levels. N Engl. J. Med. (1998) 338:1349–1357.
   Google Scholar
• ••A secondary prevention trial showing theeffect of pravastatin on CHD-related morbidity and mortality in patients with established CHD.
   Google Scholar
• PITT B, WATERS D, BROWN WV et al: Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl. J. Med (1999) 341:70–76.
   PubMed Web of Science ®Google Scholar
• ••A secondary prevention trial comparingatorvastatin versus revascularisation treatment in patients with stable coronary disease.
   Google Scholar
• SCHWARTZ GG, OLSSON AG, EZEKOWITZ MD et al.: Effects of atorvastatin on early recurrent ischaemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA (2001) 285:1711–1718.
   PubMed Web of Science ®Google Scholar
• ••A secondary prevention trial of the effectsof intensive cholesterol lowering with 80 mg of atorvastatin on cardiovascular morbidity and mortality after acute coronary syndrome.
   Google Scholar
• SERRUYS PWJC, DE FEYTER P, MACAYA N et al.: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. "AMA (2002) 287:3215–3222.
   Google Scholar
• LEVY RI: A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin. Circulation (1993) 87\(Suppl. 4):II145.
   Google Scholar
• JONES P, KAFONEK S, LAURORA I et al.: Comparative dose efficay study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am. J. Cardiol (1998) 81:582–587.
   PubMed Web of Science ®Google Scholar
• HOERGER TJ, BALA MV, BRAY JM, WILCOSKY TC, LAROSA J: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. Am. Cardiol (1998) 82:61–65.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, LAURORA I, CHU H, KAFONEK S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low density lipoprotein goals. Arch. Intern. Med (2000) 160:459–467.
   PubMed Web of Science ®Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the national cholesterol education program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• ••Most recent recommendations of the NCEP for therapeutic intervention in dyslipidearnia.
   Google Scholar
• BROWN WV: Novel approaches to lipid lowering: what is on the horizon? Am. J. Cardiol (2001) 87(Suppl.):23B–27B.
   Google Scholar
• BRUCKERT E: New advances in lipid-modifying therapies for reducing cardiovascular risk. Cardiology (2002) 97:59–66.
   PubMed Web of Science ®Google Scholar
• EVANS M, ROBERTS A, REES A: The future direction of cholesterol-lowering therapy. Curt: Opin. Lipidol. (2002) 13:663–669.
   PubMed Web of Science ®Google Scholar
• SUDHOP T, BERGMANN KV: Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs (2002) 62:2333–2347.
   PubMed Web of Science ®Google Scholar
• •Good review about new therapeutic approaches in lipid-lowering drugs focusing on compounds that lower cholesterol absorption.
   Google Scholar
• McKENNEY JM: New cholesterol guidelines, new treatment challenges. Phannacotherapy (2002) 22:853–863.
   PubMed Web of Science ®Google Scholar
• GOTTO AM Jr: Treating hypercholesterolemia: looking forward. Clin. Cardiol (2003) 26(Suppl. I) :121–128.
   Google Scholar
• HOERGER TJ, BALA MV, BRAY JM, WILCOSKY TC, LAROSA J: Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatmenteligible United States adults. Am. J. Cardiol (1998) 82:61–65.
   PubMed Web of Science ®Google Scholar
• PEARSON TA, LAURORA I, CHU H, KAFONEK S: The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipidlowering therapy and achieving low density lipoprotein goals. Arch. Intern. Med. (2000) 160:459–467.
   PubMed Web of Science ®Google Scholar
• EXPERT PANEL ON DETECTION, EVALUATION, AND TREATMENT OF HIGH BLOOD CHOLESTEROL IN ADULTS: Executive summary of the third report of the national cholesterol education program (NECP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA (2001) 285:2486–2497.
   PubMed Web of Science ®Google Scholar
• •• Most recent recommendations of the NCEP for therapeutic intervention in dyslipideamia.
   Google Scholar
• BROWN WV: Novel approaches to lipid lowering: what is on the horizon? Am. J. Cardiol. (2001) 87(Suppl.):23B–27B.
   Google Scholar
• BRUCKERT E: New advances in lipidmodifying therapies for reducing cardiovascular risk. Cardiology (2002) 97:59–66.
   PubMed Web of Science ®Google Scholar
• EVANS M, ROBERTS A, REES A: The future direction of cholesterol-lowering therapy. Curr. Opin. Lipidol. (2002) 13:663–669.
   PubMed Web of Science ®Google Scholar
• SUDHOP T, BERGMANN KV: Cholesterol absorption inhibitors for the treatment of hypercholesterolemia. Drugs (2002) 62:2333–2347.
   PubMed Web of Science ®Google Scholar
• • Good review about new therapeutic approaches in lipid-lowering drugs focusing on compounds that lower cholesterol absorption.
   Google Scholar
• McKENNEY JM: New cholesterol guidelines, new treatment challenges. Pharmacotherapy (2002) 22:853–863.
   PubMed Web of Science ®Google Scholar
• GOTTO AM Jr: Treating hypercholesterolemia: looking forward. Clin. Cardiol. (2003) 26(Suppl. I):I21–I28.
   Google Scholar
• BRUCKERT E: New lipid-modifying therapies. Expert Opin. Investig. Drugs (2003) 12:325–335.
   PubMed Web of Science ®Google Scholar
• •An excellent review on new cholesterol-lowering therapies.
   Google Scholar
• DIETSCHY JM, TURLEY SD, SPADY DK: Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. I. LipidRes. (1993) 34:1637–1659.
   PubMed Web of Science ®Google Scholar
• BOSNER MS, LANGE LG, STENSON WE OSTLUND RE Jr: Percent cholesterol absorption in normal women and men quantified with dual stable isotopic tracers and negative ion mass spectrometry. J. Lipid Res. (1999) 40:302–308.
   PubMed Web of Science ®Google Scholar
• HUSSAIN MM: A proposed model for theassembly of chylomicrons. Atherosclerosis (2000) 148:1–15.
   PubMed Web of Science ®Google Scholar
• OSTLUND RE Jr: Cholesterol absorption. Carr. Opin. Castroenterol (2002) 18:254–258.
   PubMed Web of Science ®Google Scholar
• DAWSON PA, RUDEL LL: Intestinal cholesterol absorption. Curt: Opin. Lipidol. (1999) 10:315–320.
   PubMed Web of Science ®Google Scholar
• SHEPHERD J: The role of the exogenous pathway in hypercholesterolemia. Eur. Heart. J. (2001) 3(Suppl. E):E2–E5.
   Google Scholar
• REPA JJ, TURLEY SD, LOBACCARO JMA et al: Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science (2000) 289:1524–1529.
   PubMed Web of Science ®Google Scholar
• TAKEMOTO M, LIAO JK: Pleitropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscier. a/MA V3SC. Biol. (2001) 21:1712–1719.
   PubMed Web of Science ®Google Scholar
• McTAGGART F, BUCKETT L, DAVIDSON R et al.: Preclinical and clinical pharmacology of rosuvastatin, a new 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitor. Am. J. Cardiol (2001) 87(Suppl. 5a):28B–32B.
   Google Scholar
• •A review on the chemical, pharmacodynarnic and pharmacokinetic properties of rosuvastatin.
   Google Scholar
• WHITE CM: A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. ./. Clin. Pharmacol (2002) 42:963–970.
   PubMed Web of Science ®Google Scholar
• CARSWELL CI, PLOSKER GL, JARVIS B: Rosuvastatin. Drugs (2002) 62:2075–2085.
   PubMed Web of Science ®Google Scholar
• •An exhaustive review on pharmacodynarnic and pharmacokinetic properties and therapeutic trials of rosuvastatin in patients with dyslipidaemias.
   Google Scholar
• OLSSON AG, McTAGGART F, RAZA ALI: Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc. Drug Rev (2002) 20:303–328.
   PubMedGoogle Scholar
• •Excellent and complete review on rosuvastatin.
   Google Scholar
• DAVIDSON MH: Rosuvastatin: a highly efficacious statin for the treatment of dyslipidaemia. Expert Opin. Investig. Drugs (2002) 11:125–141.
   Web of Science ®Google Scholar
• •A detailed review on clinical efficacy of rosuvastatin.
   Google Scholar
• CHENG-LAI A: Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Heart D AK (2003) 5:72–78.
   PubMedGoogle Scholar
• •A thorough and updated review of rosuvastatin.
   Google Scholar
• RADER DJ, DAVIDSON MH, CAPLAN RJ, PEARS JS: Lipid and apolipoprotein ratios: association with coronary artery disease and effects of rosuvastatin compared with atorvastatin, pravastatin, and simvastatin. Am. Cardiol (2003) 6:20C–23C.
   Google Scholar
• SHEPHERD J, HUNNINGHAKE DB, BARTER P, McKENNEY JM, HUTCHINSON HG: Guidelines for lowering lipids to reduce coronary artery disease risk: a comparison of rosuvastatin with atorvastatin, pravastatin, and simvastatin for achieving lipid-lowering goals. Am. J. Cardiol. (2003) 6:11C–17C.
   Google Scholar
• IGEL M, SUDHOP T, VON BERGMANN K: Pharmacology of 3-hydroxy-3-methyl-glutarylcoenzyme A reductase inhibitors (statins) including rosuvastatin and pitavastatin. Clin. Pharmaco] (2002) 42:835–845.
   Google Scholar
• •An updated review on the pharmacology of rosuvastatin and pitavastatin.
   Google Scholar
• NESS CG, ZHAO Z, LOPEZ D: Inhibitors of cholesterol biosynthesis increase hepatic low density lipoprotein receptor protein degradation. Arch. Biochem. Biophys. (1996) 325:242–248.
   PubMed Web of Science ®Google Scholar
• CHONG PH, YIM BT: Rosuvastatin for the treatment of patients with hypercholesterolemia. Ann. Pharmacother (2002) 36:93–101.
   PubMed Web of Science ®Google Scholar
• WARWICK MJ, DANE AL, RAZA A et al.: Pharmacokinetic and safety profile for the new HMG-CoA reductase inhibitor ZD4522 (single and multiple doses). Can. J. Cardiol (2000) 16(Suppl. F):19F.
   Google Scholar
• MARTIN PD, DANE AL, SCHNECK DW et al.: Pharmacodynamic effects and pharmacokinetics of new HMG-CoA reductase inhibitor ZD4522 after AM and PM administration in healthy subjects. Pharmaco] (2000) 40:1056.
   Google Scholar
• ROACH AE, TSIKOURIS JP, HAASE KK: Rosuvastatin. A new HMG-CoA reductasa inhibitor for hypercholesterolemia. Formulary (2002) 37:179–185.
   Google Scholar
• OLSSON AG, PEARS J, McKELLAR J, MIZAN J, RAZA A: Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol (2001) 88:504–508.
   PubMed Web of Science ®Google Scholar
• PAOLETTI R, FAHMY M, MAHLA G, MIZAN J, SOUTHWORTH H: Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. Cardiovasc. Risk (2001) 8:383–390.
   PubMedGoogle Scholar
• OLSSON AG, ISTAD H, LUURILA 0 et al.: Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Am. Heart j (2002) 144:1044–1051.
   Google Scholar
• •A randomised, double-blind, parallel-group, multinational, multi-centre trial showing the effects of rosuvastatin and atorvastatin in patients with hypercholesterolaemia.
   Google Scholar
• BROWN WV, BAYS HE, HASSMAN DR et al.: Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Am. Heart J. (2002) 144:1036–1043.
   PubMed Web of Science ®Google Scholar
• •A randomised, double-blind, parallel-group, controlled trial showing the efficacy of rosuvastatin compared with that of pravastatin and simvastatin in patients with hypercholesterolaemia.
   Google Scholar
• DAVIDSON M, MA P, STEIN EA et al: Comparison of effects of low-density lipoprotein cholesterol and high-desity lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with Type IIa or IIb hypercholesterolemia. Am. Cardiol (2002) 89:268–275.
   PubMed Web of Science ®Google Scholar
• BREWER HB Jr: Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. Cardiol (2003) 92:23K–29K.
   Google Scholar
• JONES PH, DAVIDSON MH, STEIN EA et al.: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am. j Cardio] (2003) 92:152–160.
   PubMed Web of Science ®Google Scholar
• SCHUSTER H: Rosuvastatin - a highly effective new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor: review of clinical data at 10-40 mg doses in dyslipidemic patients. Cardiology (2003) 99:126–139.
   PubMed Web of Science ®Google Scholar
• BERRY DAM, BERRY SM, MCKELLAR J, PEARSON TA: Comparison of the dose-response relationships of 2 lipid-lowering agents: a Bayesian meta-analysis. Am. Heart j (2003) 145:1036–1045.
   PubMed Web of Science ®Google Scholar
• STALKER TJ, LEFER AM, SCALIA R: A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br. J. Pharmacol (2001) 133:406–412.
   PubMed Web of Science ®Google Scholar
• KNOPP RH: Drug treatment of lipid disorders. N Engl. I Med (1999) 341:498–511.
   PubMed Web of Science ®Google Scholar
• FLORES NA: Pitavastatin. Can: Opin. Investig. Drugs (2002) 3:1334–1341.
   Google Scholar
• •A concise and up-to-date review of pitavastatin.
   Google Scholar
• KAJINAMI K, MABUCHI H, SAITO Y: NK-104: a novel synthetic HMG-CoA reductase inhibitor. Expert Opin. Investig. Drugs (2000) 9:2653–2661.
   PubMed Web of Science ®Google Scholar
• ISLEY WL: Pitavastatin (NK-104), a new HMG-CoA reductase inhibitor. Drugs Today (2001) 37:587–594.
   PubMed Web of Science ®Google Scholar
• KOJIMA J, FUJINO H, YOSIMURA M, MORIKAWA H, KIMATA H: Simultaneous determination of NK-104 and its lactone in biological samples by column-switching high-performance liquid chromatography with ultraviolet detection. Chromatogr. B. Biomed. Sci. Appl. (1999) 724:173–180.
   PubMed Web of Science ®Google Scholar
• KAJINAMI K, KOIZUMI J, UEDA K et al: Effects of NK-104, a new hydroxymethylglutaryl-coenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am. Cardiol (2000) 85:178–183.
   PubMed Web of Science ®Google Scholar
• •Study on the efficacy and safety of pitavastatin monotherapy in patients with heterozygous familial hypercholesterolaemia.
   Google Scholar
• SAITO Y, YAMADA N, TERAMOTO T et al.: A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis (2002) 162:373–379.
   PubMed Web of Science ®Google Scholar
• •Comparative study of pitavastatin and pravastatin in hypercholesterolaemia.
   Google Scholar
• SAITO Y, YAMADA N, TERAMOTO T et al.: Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor in patients with hyperlipidemia. Dose-finding study using the double-blind, three-group parallel comparison. Arzneimittelforschung (2002) 52:251–255.
   Google Scholar
• NOJI Y, HIGASHIKATA T, INAZU A et al.: Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 163:157–164.
   PubMed Web of Science ®Google Scholar
• NEIL HA, MEIJER GW, ROE LS: Randomised controlled trial of use by hypercholesterolaemic patients of a vegetable oil sterol-enriched fat spread. Atherosclerosis (2001) 156:329–337.
   PubMed Web of Science ®Google Scholar
• LAW M: Plant sterol and stanol margarines and health. Br. Med.' (2001) 320:861–864.
   Web of Science ®Google Scholar
• BEIL FU, GRUNDY SM: Studies on plasma lipoproteins during absorption of exogenous lecithin in man. Lipid. Res (1980) 21:525–536.
   PubMed Web of Science ®Google Scholar
• JANDACEK RJ, RAMIREZ MM, CROUSE JR 3rd: Effects of partial replacement of dietary fat by olestra on dietary cholesterol absorption in man. Metabolism (1990) 39:848–852.
   PubMed Web of Science ®Google Scholar
• GYLLING H, MIETTINEN TA: The effect of cholesterol absorption inhibition on low density lipoprotein cholesterol level. Atherosclerosis (1995) 117:305–308.
   PubMed Web of Science ®Google Scholar
• MITTENDORFER B, OSTLUND RE Jr, PATTERSON BW, KLEIN S: Orlistat inhibits dietary cholesterol absorption. Obes. Res. (2001) 9:599–604.
   PubMedGoogle Scholar
• VAN HEEK M, FARLEY C, COMPTON DS, HOOS LM, SMITH-TORHAN A, DAVIS HR: Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br: J. Pharmacol (2001) 134:409–417.
   PubMed Web of Science ®Google Scholar
• CATAPANO AL: Ezetimibe: a selective inhibitor of cholesterol absorption. Ear: Heart (2001) 3(Suppl. E):E6–E10.
   Google Scholar
• GUPTA EK, ITO MK: Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors. Heart D AK (2002) 4:399–409.
   PubMedGoogle Scholar
• •A recent and exhaustive review of ezetimibe.
   Google Scholar
• BAYS H: Ezetimibe. Expert Opin. Investig. Drugs (2002) 11:1587–1604.
   PubMed Web of Science ®Google Scholar
• •A detailed review on the efficacy, safety and tolerability of ezetimibe.
   Google Scholar
• DARKES MJM, POOLE RM, GOA KL: Ezetimibe. Am. .1. Cardiovasc. Drugs (2003) 3:67–76.
   Google Scholar
• •A recent and interesting review of ezetimibe.
   Google Scholar
• SUDHOP T, LOTJOHANN D, KODAL A et al: Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation (2002) 106:1943–1948.
   PubMed Web of Science ®Google Scholar
• BAYS HE, MOORE PB, DREHOBL MA et al.: Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase studies. Clin. Ther (2001) 23:1209–1230.
   PubMed Web of Science ®Google Scholar
• PATRICK JE, KOSOGLOU T, STAUBER KL et al: Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects. Drug Dispos (2002) 30:430–437.
   PubMed Web of Science ®Google Scholar
• VAN HEEK M, DAVIS H: Pharmacology of ezetimibe. Ear: Heartj Sapp]. (2002) 4(Suppl. J):J17–J20.
   Google Scholar
• VAN HEEK M, FARLEY C, COMPTON DS et al: Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, 5CH58235, and its glucuronide, 5CH60663. Br. J. Pharmacol. (2000) 129:1748–1754.
   PubMed Web of Science ®Google Scholar
• ZHU Y, STATKEVICH P, KOSOGLOU T et al.: Effects of ezetimibe (SCH 58235) on the activity of drug metabolizing enzymes in vivo. Clin. Pharmacol. Ther. (2000) 67:152.
   Web of Science ®Google Scholar
• EZZET F, WEXLER D, STATKEVICH Pet al.: The plasma concentrations and LDL-C relationship in patients receiving ezetimibe. Clin. Pharmacol (2001) 41:943–949.
   Google Scholar
• VAN HEEK M, FARLEY C, COMPTON DS et al.: The potent cholesterol absorption inhibitor, ezetimibe, is glucuronidated in the intestine, localizes to the intestine, and circulates enterohepatically. Atherosclerosis (2000) 151:155A.
   Google Scholar
• KNOPP RH, GITTER H, TRUITT T et al.: Ezetimibe reduces low-density lipoprotein cholesterol: results of a Phase III, randomized, double-blind, placebo-controlled trial. Atherosclerosis (2001) 2\(Suppl. 2):38A.
   Google Scholar
• DUJOVNE CA, ETTINGER MP, McNEER JF et al.: Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. Cardiol. (2002) 90:1092–1097.
   PubMed Web of Science ®Google Scholar
• •A randomised, double-blind, placebo-controlled showing the efficacy and safety of ezetimibe monotherapy in patients with primary hypercholesterolaemia.
   Google Scholar
• GAGNE C, BAYS HE, WEISS SR et al: Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am.j Cardiol (2002) 90:1084–1091.
   PubMed Web of Science ®Google Scholar
• •A randomised, double-blind, placebo-controlled study showing the efficacy and safety of adding ezetimibe to ongoing statin therapy in patients with primary hypercholesterolaemia.
   Google Scholar
• GAGNE C, GAUDET D, BRUCKERT E, THE EZETIMIBE STUDY GROUP: Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation (2002) 105:2469–2475.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, McGARRY T, BETTIS R et al.: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. Am. Coll Cardiol. (2002) 40:2125–2134.
   PubMed Web of Science ®Google Scholar
• BAYS HE, WEISS S, GAGNE C et al: Ezetimibe added to ongoing statin therapy for treatment of primary hypercholesterolemia. j Am. Coll. Cardiol. (2002) 39(5, Suppl. A):833–834.
   Google Scholar
• LIPKA L, KERZNER B, CORBELLI J et al.: Ezetimibe coadministered with lovastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):430B.
   Google Scholar
• MELANI L, MILLS R, HASSMAN D et al.: Ezetimibe coadministered with pravastatin in 538 patients with primary hypercholesterolemia. J. Am. Coll. Cardiol. (2002) 39(Suppl. B):139B.
   Google Scholar
• BALLANTYNE C, HOURI J, NOTARBARTOLO A et al: Ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia. J. Am. Coll Cardiol (2002) 39(5, Suppl. A):227A.
   Google Scholar
• DAVIS HR Jr, PULA KK, ALTON KB et al.: The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in dogs. Metabolism (2001) 50:1234–1241.
   PubMed Web of Science ®Google Scholar
• SUCKLING KE, STANGE EF: Role of acyl-CoA: cholesterol acyltransferase in cellular cholesterol metabolism. J. Lipid Res. (1985) 26:647–671.
   PubMed Web of Science ®Google Scholar
• RUDEL LL, LEE RG, COCKMAN TL: Acyl coenzyme A. Cholesterol acyltransferase types 1 and 2: structure and function in atherosclerosis. Curt: Opin. Lipidol (2001) 12:121–127.
   Google Scholar
• OELKERS P, BEHARI A, CROMLEY D et al.: Characterization of two human genes encoding acyl coenzyme A: cholesterol acyltransferase-related enzymes. J. Biol. Chem. (1998) 273:26755–26764.
   PubMedGoogle Scholar
• LLAVERIAS G, LAGUNA JC, ALEGRET M: Pharmacology of the ACAT inhibitor avasimibe (CI-1011). Cardiovasc. Drug Rev (2003) 21:33–50.
   PubMedGoogle Scholar
• LEE HT, SLISKOVIC DR, PICARD JA et al.: Inhibitors of acyl-CoA: cholesterol 0-acyl transferase (ACAT) as hypocholesterolemic agents. CI-1011: an acyl sulfamate with unique cholesterol-lowering activity in animals fed noncholesterol-supplemented diets. J. Med. Chem. (1996) 39:5031–5034.
   Google Scholar
• RAMHARACK R, SPAHR MA, SEKERKE CS et al: CI-1011 lowers lipoprotein (a) and plasma cholesterol concentrations in chow-fed cynomolgus monkeys. Atherosclerosis (1998) 136:79–87.
   PubMed Web of Science ®Google Scholar
• BURNETT JR, WILCOX LJ, TELFORD DE et al.: Inhibition of ACAT by avasimibe decreases both VLDL and LDL apolipoprotein B production in miniature pigs. I Lipid Res. (1999) 40:1317–1327.
   PubMed Web of Science ®Google Scholar
• INSULL W Jr, TOTH P, MULLICAN W et al.: Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin. Proc. (2001) 76:971–982.
   PubMed Web of Science ®Google Scholar
• DELSING DJ, OFFERMAN EH, VAN DUYVENVOORDE W et al: Acyl-CoA: cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice. Circulation (2001) 103: 1778-1786.
   Google Scholar
• NICOLOSI RJ, WILSON TA, KRAUSE BR: The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty steak area in hamsters. Atherosclerosis (1998) 137:77–85.
   PubMed Web of Science ®Google Scholar
• BOCAN TM, KRAUSE BR, ROSEBURY WS et al.: The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression. Atherosclerosis (2001) 157:97–105.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ A, USHER DC: Anti-atherogenic effects of the acyl-CoA: cholesterol acyltransferase inhibitor, avasimibe (CI-1011), in cultured primary human macrophages. Atherosclerosis (2002) 161:45–54.
   PubMed Web of Science ®Google Scholar
• LLAVERIAS G, JOVE M, VAZQUEZ-CARRERA M et al.: Avasimibe and atorvastatin synergistically reduce cholesterol ester content in THP-1 macrophages. Eui: Pharmacol (2002) 451:11–17.
   PubMed Web of Science ®Google Scholar
• TARDIF JC, GREGOIRE J, LESPERANCE J et al.: Design features of the Avasimibe and Progression of coronary Lessions assessed by intravascular UltraSound (A-PLUS) clinical trial. Am. Heart J. (2002) 144:589–596.
   PubMed Web of Science ®Google Scholar
• GORDON DA, JAMIL H: Progress towards understanding the role of microsomal triglyceride transfer protein in apolipoprotein-B lipoprotein assembly. Biochem. Biophys. Acta (2000) 1486:72–83.
   PubMed Web of Science ®Google Scholar
• CHANG G, RUGGERI RB, HARWOOD HJ Jr: Microsomal triglyceride transfer protein (MTP) inhibitors: discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms. Curt: Opin. Drug Discov. Devel (2002) 5:562–570.
   PubMed Web of Science ®Google Scholar
• SHIOMI M, ITO T: MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion. Eur: Pharmacol (2001) 431:127–131.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, DICKLIN MR, MAKI KC, KLEINPELL RIVI: Colesevelam hydrochloride: a non-absorbed, polymeric cholesterol-lowering agent. Expert Opin. Investig. Drugs (2000) 9:2663–2671.
   PubMed Web of Science ®Google Scholar
• ALDRIDGE MA, ITO MK: Colesevelam hydrochloride: a novel bile acid-binding resin. Ann. Pharmacother. (2001) 35:898–907.
   PubMed Web of Science ®Google Scholar
• STEINMETZ KL: Colesevelam hydrochloride. Am. I Health Syst. Pharm (2002) 15:932–939.
   Google Scholar
• BAYS H, DUJOVNE C: Colesevelam HC1: a non-systemic lipid altering drug. Expert Opin. Pharmacother. (2003) 4:779–790.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, DILLON MA, GORDON B et al.: Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch. Intern. Med. (1999) 159:1893–1900.
   PubMed Web of Science ®Google Scholar
• INSULL W Jr, KOREN M, DAVIGNON J et al: Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis (2001) 157:137–144.
   PubMed Web of Science ®Google Scholar
• WONG NN: Colesevelam: a new bile acid sequestrant. Heart Dis. (2001) 3:63–70.
   PubMedGoogle Scholar
• KNAPP HH, SCHROTT H, MA P et al: Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am. J. Med. (2001) 110:352–360.
   PubMed Web of Science ®Google Scholar
• DAVIDSON MH, TOTH P, WEISS S et al.: Low-dose combination therapy with colesevelam hydrochloride and lovastatin effectively decreases low-density lipoprotein cholesterol in patients with primary hypercholesterolemia. Cliii. Cardiol (2001) 24:467–474.
   PubMed Web of Science ®Google Scholar
• HUNNINGHAKE D, INSULL W Jr, TOTH P, DAVIDSON D, DONOVAN JM, BURKE SK: Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis (2001) 158:407–416.
   PubMed Web of Science ®Google Scholar
• DONOVAN JM, STIPINSKI D, STILES MR, OLSON TA, BURKE SK: Drug interactions with colesevelam hydrochloride, a novel, potent lipid-lowering agent. Cardiovasc. Drugs Thor (2000) 14:681–690.
   PubMed Web of Science ®Google Scholar